ADH 1

Drug Profile

ADH 1

Alternative Names: ADH-1; ADH-100001; Exherin

Latest Information Update: 23 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator McGill University
  • Developer Adherex Technologies
  • Class Antineoplastics; Cyclic peptides; Oligopeptides
  • Mechanism of Action Angiogenesis inhibitors; Cadherin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Apr 2009 Preclinical drug interactions data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 02 Jun 2008 Interim efficacy data from a phase I trial in Malignant melanoma released by Adherex Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top